Anak Agung Ngurah Krisnanta Adnyana
Research Subjects
Anak Agung Ngurah Krisnanta Adnyana has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Anak Agung Patriana Puspaningrat
Department of Urology, Wangaya General Hospital, Denpasar, Bali
1 shared publication - Gede Wirya Kusuma Duarsa
Department of Urology Surgery, Prof. Dr. I.G.N.G. Ngoerah General Hospital, Bali
1 shared publication - I Wayan Suarsana
Wangaya General Hospital, Denpasar, Bali
1 shared publication - Ida Bagus Oka Widya Putra
Wangaya General Hospital, Denpasar, Bali
1 shared publication - Marshal Harvy Wicaksono Pantjoro
Department of Urology Surgery, Prof. Dr. I.G.N.G. Ngoerah General Hospital, Bali
1 shared publication
Latest Publications
- Open Access
- 30 June 2025
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 97 (2) , 13903
Evaluating hormonal differences in post-orchidopexy patients: a meta-analysis of palpable vs. nonpalpable undescended testis
Introduction: Cryptorchidism or undescended testis (UDT) is one of the most common congenital anomalies in male infants. Based on the physical examination, UDT can be classified into palpable and non-palpable. However, despite successful repositioning, the long-term function of the testis is still a concern. This meta-analysis aims to compare the testicular function of palpable UDT and non-palpable UDT post-orchidopexy using hormonal markers such as FSH, LH, and testosterone. Materials and methods: A comprehensive literature search was performed using PubMed, ScienceDirect, and Google Scholar databases up to March 2025. Statistical analyses were conducted using Review Manager (RevMan). Results: Four eligible studies were included in the analysis, involving 207 patients who underwent orchidopexy for UDT, including 160 with palpable UDT and 47 with non-palpable UDT. There is no significant difference between palpable compared to non-palpable in terms of FSH (MD 0.78 IU/L [95% CI: -0.34 to 1.90], p = 0.14); LH (MD -0.17 IU/L [95% CI: -0.45 to 0.12], p = 0.25); and testosterone (-0.08 IU/L [95% CI: -0.64 to 0.48], p = 0.78).Conclusions: Testicular functions, including FSH, LH, and testosterone, in palpable UDT did not differ significantly from those in non-palpable UDT.
- 30 June 2025
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 97 (2) , 13903
Open AccessEvaluating hormonal differences in post-orchidopexy patients: a meta-analysis of palpable vs. nonpalpable undescended testis
Introduction: Cryptorchidism or undescended testis (UDT) is one of the most common congenital anomalies in male infants. Based on the physical examination, UDT can be classified into palpable and non-palpable. However, despite successful repositioning, the long-term function of the testis is still a concern. This meta-analysis aims to compare the testicular function of palpable UDT and non-palpable UDT post-orchidopexy using hormonal markers such as FSH, LH, and testosterone. Materials and methods: A comprehensive literature search was performed using PubMed, ScienceDirect, and Google Scholar databases up to March 2025. Statistical analyses were conducted using Review Manager (RevMan). Results: Four eligible studies were included in the analysis, involving 207 patients who underwent orchidopexy for UDT, including 160 with palpable UDT and 47 with non-palpable UDT. There is no significant difference between palpable compared to non-palpable in terms of FSH (MD 0.78 IU/L [95% CI: -0.34 to 1.90], p = 0.14); LH (MD -0.17 IU/L [95% CI: -0.45 to 0.12], p = 0.25); and testosterone (-0.08 IU/L [95% CI: -0.64 to 0.48], p = 0.78).Conclusions: Testicular functions, including FSH, LH, and testosterone, in palpable UDT did not differ significantly from those in non-palpable UDT.
- Open Access
- 30 June 2025
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 97 (2) , 13856
Exploring the association between hemoglobin, hematocrit, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio with erectile dysfunction in chronic kidney disease patients undergoing hemodialysis: a cross-sectional study
Erectile dysfunction (ED) is one of the complications in male patients with end-stage chronic kidney disease (CKD). Renal replacement therapy may improve general conditions and thus improve erectile function. This study aims to determine changes in erectile dysfunction in end-stage CKD patients who underwent hemodialysis, focusing on changes in laboratory parameters. This cross-sectional study was conducted from March to April 2024 at the Hemodialysis Unit of Wangaya General Hospital. The subjects were male patients with end-stage chronic kidney disease (CKD) who were undergoing hemodialysis and met the specific inclusion and exclusion criteria. Erectile function was assessed using the International Index of Erectile Function (IIEF- 5) and the Erection Hardness Score (EHS). Laboratory parameters, including hemoglobin, hematocrit, neutrophil count, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) were recorded. Twenty-two subjects were included in this study. The prevalence of ED before starting hemodialysis and after a period of at least 3 months of hemodialysis was 28.3% and 86.4% respectively. A statistically significant difference was observed in the IIEF-5 scores of patients before and after hemodialysis (p=0.001). Significant differences were observed in the erection degree before and after hemodialysis based on IIEF-5 (p=0.001) and EHS (p=0.001). There was a significant correlation between erection degree assessed by IIEF-5 and hemoglobin, hematocrit, NLR and PLR; and erection degree assessed by EHS and hemoglobin, hematocrit, and PLR, (all p<0.05). In conclusion, there is a deterioration in erectile function in patients undergoing hemodialysis compared to their condition before hemodialysis. There was a significant correlation between hemoglobin, hematocrit, NLR, and PLR and erectile dysfunction.
- 30 June 2025
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 97 (2) , 13856
Open AccessExploring the association between hemoglobin, hematocrit, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio with erectile dysfunction in chronic kidney disease patients undergoing hemodialysis: a cross-sectional study
Erectile dysfunction (ED) is one of the complications in male patients with end-stage chronic kidney disease (CKD). Renal replacement therapy may improve general conditions and thus improve erectile function. This study aims to determine changes in erectile dysfunction in end-stage CKD patients who underwent hemodialysis, focusing on changes in laboratory parameters. This cross-sectional study was conducted from March to April 2024 at the Hemodialysis Unit of Wangaya General Hospital. The subjects were male patients with end-stage chronic kidney disease (CKD) who were undergoing hemodialysis and met the specific inclusion and exclusion criteria. Erectile function was assessed using the International Index of Erectile Function (IIEF- 5) and the Erection Hardness Score (EHS). Laboratory parameters, including hemoglobin, hematocrit, neutrophil count, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) were recorded. Twenty-two subjects were included in this study. The prevalence of ED before starting hemodialysis and after a period of at least 3 months of hemodialysis was 28.3% and 86.4% respectively. A statistically significant difference was observed in the IIEF-5 scores of patients before and after hemodialysis (p=0.001). Significant differences were observed in the erection degree before and after hemodialysis based on IIEF-5 (p=0.001) and EHS (p=0.001). There was a significant correlation between erection degree assessed by IIEF-5 and hemoglobin, hematocrit, NLR and PLR; and erection degree assessed by EHS and hemoglobin, hematocrit, and PLR, (all p<0.05). In conclusion, there is a deterioration in erectile function in patients undergoing hemodialysis compared to their condition before hemodialysis. There was a significant correlation between hemoglobin, hematocrit, NLR, and PLR and erectile dysfunction.